Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Leases (2019 - 2023)

Historic Capital Leases for Beam Therapeutics (BEAM) over the last 5 years, with Q3 2023 value amounting to $304000.0.

  • Beam Therapeutics' Capital Leases fell 7809.8% to $304000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $304000.0, marking a year-over-year decrease of 7809.8%. This contributed to the annual value of $1.2 million for FY2022, which is 6162.29% down from last year.
  • As of Q3 2023, Beam Therapeutics' Capital Leases stood at $304000.0, which was down 7809.8% from $875000.0 recorded in Q2 2023.
  • In the past 5 years, Beam Therapeutics' Capital Leases ranged from a high of $5.3 million in Q1 2020 and a low of $304000.0 during Q3 2023
  • Its 5-year average for Capital Leases is $3.0 million, with a median of $3.3 million in 2021.
  • In the last 5 years, Beam Therapeutics' Capital Leases skyrocketed by 2001.81% in 2020 and then crashed by 7809.8% in 2023.
  • Quarter analysis of 5 years shows Beam Therapeutics' Capital Leases stood at $4.4 million in 2019, then increased by 20.02% to $5.3 million in 2020, then crashed by 43.2% to $3.0 million in 2021, then plummeted by 61.62% to $1.2 million in 2022, then crashed by 73.66% to $304000.0 in 2023.
  • Its last three reported values are $304000.0 in Q3 2023, $875000.0 for Q2 2023, and $983000.0 during Q1 2023.